Anzeige
Mehr »
Login
Dienstag, 07.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Diese Aktie hebt ab: +130,67% Kursgewinn in 1 Monat – das sind die Gründe
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
37 Leser
Artikel bewerten:
(0)

Cell-Free DNA (cfDNA) Markets, 2021: Consumables, Systems/Hardware, Services - Research and Markets

DUBLIN, Apr. 07, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Cell-Free DNA (cfDNA) Markets: Consumables, Systems/Hardware, Services" report to their offering.

Research and Markets Logo

The use of cell-free DNA (cfDNA) and liquid biopsies of other analytes has received a huge amount of attention in recent years, due to its potential to revolutionize the diagnosis and treatment of several conditions. The main areas where cfDNA analysis has turned into a major application include non-invasive prenatal testing (NIPT); oncology, circulating tumor DNA (ctDNA); and transplantation, donor-derived cell-free DNA (ddcfDNA).

Cell-Free DNA (cfDNA) Markets focuses on the market for cfDNA analysis instruments, consumables, kits, and related software, which includes the sample preparation products and equipment as well as the next generation sequencing (NGS) and digital polymerase chain reaction (dPCR) systems used for detection.

The report provides complete market information, including current market estimates and forecasts to 2021, as well as:

- Growth Rate for cfDNA Market, 2015-2021
- cfDNA Clinical Diagnostics Market, 2015-2021
- cfDNA Clinical Diagnostics Market Growth Rate, 2015-2021
- cfDNA Market by Region, 2015 (N. America, Europe, Asia-Pacific & ROW)
- cfDNA Instruments and Consumables Revenues by Product Type, 2015 (Consumables, Systems/hardware, Services)
- Market Share by Company of the cfDNA Analysis Instruments, Consumables, and Software Market, 2015

The report provides information on cfDNA analysis products, commenting not only on reagents, consumables, kits, systems, software, and services, but also on oncology cfDNA products, cfDNA transplantation diagnostics, and other products employing cfDNA.

In the cfDNA market there are many technical challenges to overcome, along with a range of competitive, regulatory, and IP issues. Cancer is a dynamic and defiant disease. While NIPT is a proven application, oncology will require much more difficult work and is more uncertain. The variety of potential issues and threats in the market are covered in the challenges and strategic recommendations chapter of the report. The competitive situation, deals, and litigation are covered in respective chapters as well.

Cell-Free DNA (cfDNA) Markets covers not just the dynamics of the market but also its competitive landscape. For example, several companies are licensing their technologies or offering services.

The report profiles those companies competing in the cfDNA instruments and consumables market, including:

- Agilent Technologies
- Bio-Rad
- F. Hoffmann-La Roche AG
- Fluidigm
- Illumina
- Qiagen
- RainDance Technologies
- Thermo Fisher Scientific

For more information about this report visit http://www.researchandmarkets.com/research/lk3kvn/cellfree_dna

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2017 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.